Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apcmin/+ mouse

Shaw, Paul ORCID: https://orcid.org/0000-0002-7467-0619, Maughan, Timothy Stanley and Clarke, Alan Richard ORCID: https://orcid.org/0000-0002-4281-426X 2011. Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apcmin/+ mouse. British Journal of Cancer 105 (5) , pp. 649-657. 10.1038/bjc.2011.291

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (594kB) | Preview

Abstract

background: Identification of early molecular pathway changes may be useful as biomarkers for tumour response/resistance prediction, and here we provide direct in vivo proof of this concept. The type 1 insulin-like growth factor receptor (IGF1R) has been implicated in various aspects of adenoma development and metastasis. We show here that, in murine intestinal adenomas acutely exposed to a small molecular inhibitor of EGFR (gefitinib), there is concurrent suppression of EGFR downstream signalling and induction of IGF signalling. We therefore tested the hypothesis that blockade of EGFR signalling was being tempered by compensatory activation of the IGF pathway by examining the effect of chronic suppression of IGF1R using AZ12253801, a small molecular tyrosine kinase inhibitor of IGF1R. methods: Male Apcmin/+ mice with an intestinal tumour burden were exposed to a single dose of an inhibitor against EGFR (gefitinib), IGF1R (AZ12253801), 0.5% Tween 80 or combined EGFR/IGF1R inhibitor and culled 4 h post dosing. Tumour tissue was analysed to detect the early molecular pathways induced and anti-tumour phenotypic changes. Cohorts of male Apcmin/+ mice (n=15–17) were subsequently treated with gefitinib for a period of 8 weeks and subsequently exposed to single (either gefitinib or AZ12253801) or combined (gefitinib and AZ12253801) therapy. We also included a vehicle-treated cohort, which was never exposed to gefitinib and became symptomatic of the disease by day 150. results: Both single treatments delayed the onset of disease symptoms. Combined dosing with gefitinib and AZ12253801 similarly delayed the onset of symptoms, and at 200 days suppressed small intestinal tumourigenesis more effectively than either treatment alone (median small intestinal adenoma volume (47 mm3 (comb) vs 248 mm3 (AZ12253801), P=0.0003 and 47 mm3 (comb) vs 123 mm3 (gefitinib), P=0.0042, Mann–Whitney (two-sided) test). conclusion: Our data provide evidence in support of the use of combinatorial therapy, and establishes the need to further define the precise benefit in vivo.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords:	epidermal growth factor receptor; insulin-like 1 growth factor receptor; receptor tyrosine kinase inhibition; Apcmin/+ mouse
Publisher:	Nature Publishing Group
ISSN:	0007-0920
Date of First Compliant Deposit:	30 March 2016
Last Modified:	22 Nov 2024 00:15
URI:	https://orca.cardiff.ac.uk/id/eprint/71542

Citation Data

Cited 11 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item